In the GIOIA study, users of both SGLT-2i and DPP-4i improved glycometabolic control, after 12 months, independently from baseline eGFR levels. Moreover, both classes led to a significant decrease in eGFR in participants with eGFR ≥ 90 ml/min/1.73 m2 and no deterioration in case of mild impairment of renal function.
Keywords: DPP-4i; Kidney function; SGLT-2i; Type 2 diabetes; eGFR.
Copyright © 2021 Elsevier B.V. All rights reserved.